Treatment

The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP. clinical trials

2 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase III and phase IV (Integrated)
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)
This study is looking into a new treatment called tralokinumab for adults with moderate to severe eczema on their hands. It wants to see how well it works and if it's safe compared to a dummy treatment. The goal is to see if the medicine can clear up or significantly improve hand eczema in a few months.
For: Atopic dermatitis and moderate-to severe atopic hand eczema
Sweden · France · Czechia
Ongoing, recruitingTherapeutic use (Phase IV)
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial
This study compares a flexible dose of Brodalumab, a psoriasis treatment, with its usual dose for people with moderate to severe plaque psoriasis who weigh 120 kg or more. It aims to see if the adjustable dose works better at clearing skin.
For: Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
Czechia · Hungary · Italy